ABSTRACT In the National Heart, Lung and Blood Institute Type Il Coronary Intervention Study, patients with Type lI hyperlipoproteinemia and coronary artery disease (CAD) were placed on a lowfat, low-cholesterol diet and then were randomly allocated to receive either 6 g cholestyramine four times daily or placebo. This double-blind study evaluated the effects of cholestyramine on the progression of CAD as assessed by angiography. Diet alone reduced the low-density lipoprotein cholesterol 6% in both groups. After randomization, low-density lipoprotein cholesterol decreased another 5% in the placebo group and 26% in the cholestyramine-treated group. Coronary angiography was performed in 1 16 patients before and after 5 years of treatment. CAD progressed in 49% (28 of 57) of the placebotreated patients vs 32% (19 of 59) of the cholestyramine-treated patients (p < .05). When only definite progression was considered, 35% (20 of 57) of the placebo-treated patients vs 25% (15 of 59) of the cholestyramine-treated patients exhibited definite progression; the difference was not statistically significant. However, when this analysis was performed with adjustment for baseline inequalities of risk factors, effect of treatment was more pronounced. Of lesions causing 50% or greater stenosis at baseline, 33% of placebo-treated and 12% of cholestyramine-treated patients manifested lesion progression (p < .05). Similar analyses with other end points (percent of baseline lesions that progressed, lesions that progressed to occlusion, lesions that regressed, size of lesion change, and all cardiovascular end points) all favored the cholestyramine-treated group, but were not statistically significant. Thus, although the sample size does not allow a definitive conclusion to be drawn, this study suggests 
upper 10th percentile of the distribution of the general population and if they manifested presumptive evidence of CAD (previous myocardial infarction, angina, positive exercise stress test, or coronary calcification on fluoroscopy). No patient had severe incapacitating angina. Most had no symptoms or were only mildly limited on medical therapy. The only angiographic indications for exclusion from the study was the finding of more than 75% luminal narrowing of the left main coronary artery or no coronary disease meeting the criteria of 20% luminal narrowing. (Four patients, who were noted to have disease at the screening reading of the angiograms and hence were entered into the study, were later judged by the formal readings of the three panels to be free of CAD at baseline.) Patients who met the eligibility requirements and gave informed consent were continued on the diet and were randomly allocated to receive a daily dosage of 24 g cholestyramine (treatment group) or to receive placebo (control group). Dosage was adjusted in response' to side effects, most of which were gastrointestinal. The study was conducted in a double-blind manner; the patient, the physician, or the panels of angiographers that evaluated the coronary angiograms did not know the treatment assignments of individual patients. In addition, lipid values and certain other chemistries obtained during the follow-up that might provide clues as to type of treatment were not released to patients or personnel involved with patient care. Patients came to the Clinical Center at the National Institutes of' Health in Bethesda for monthly visits at which time cardiac status, diet, and drug adherence and side effects were monitored. Plasma cholesterol and triglycerides were determined every 2 months and LDL cholesterol and high-density lipoprotein (HDL) cholesterol were measured semiannually. The methods used for analyses of plasma lipids and lipoproteins have been previously published. At the end of 5 years of follow-up, each patient was hospitalized and a repeat coronary angiogram was performed.
In the planning phase, calculations of sample size indicated a desired study pop'ulation of 250 patients. However, the entry criteria were rigorous and only 143 patients could be recruited during the 54 month recruitment period of the study. Of these 143' patients, there were 1 16 who had a repeat angiogram and hence, a determination of CAD progression. Since the weight of laboratory and epidemiologic evidence suggested that reduction of lipid concentrations would retard CAD progression, the study was designed to look for benefit only. During the 5 year follow-up of the study there were 12 deaths (table 1). In addition, 10 patients withdrew from the study, and there were five patients who continued to follow their prescribed treatment regimen and attended the clinic but did not consent to angiography at 5 years. Thus, of the 143 patients who entered the study, there were 1 16 who had angiograms performed both initially and after 5 years of follow-up. Outcome determination. To establish the precision and accuracy of angiographic readings of both cine and cut films by expert angiographers, an experiment for reading angiograms was conducted. This demonstrated that agreement by at least two out of three independent review panels regarding the occurrence of change in a segment of the arterial tree was required to establish a reliable measure of such change.2 The procedure for reading the baseline and 5 year follow-up angiograms based on the results of the experiment has been reported.' In summary, the baseline and 5 year follow-up angiograms were evaluated as a pair, with the temporal sequence of the films and the treatment assignment unknown to the readers. The evaluation was per- Confirmed lesion changes. Once lesion changes observed by individual panels were aligned, a determination of change was based' upon a two of three panel majority. By definition, a confirmed change required at least two or three of the panels to agree that a change occurred. Such changes were classified as shown in table 5.
The first method of analysis focused on lesions. Since each lesion would be exposed to the same blood lipid levels, several lesions in one patient were not assumed to change independently and so the patient was considered as the primary unit of analysis. Once a definition of lesion change was established we adopted the following definition of change for a patient:
Definite progression -At least one lesion with definite progression and no lesion with regression.
Probable progression -At least one lesion with probable progression and no lesion with regression or definite progression.
Probable regression -At least one lesion with probable regression and no lesions with definite regression or any progression.
Definite regression -At least one lesion with definite regression and no progression.
Mixed response -regression and progression: lesion progression and lesion regression in the same patient, whether definite or probable. Patients with mixed response were further classified as having both definite regression, both probable progression and probable regression, or definite progression with probable regression. No change No lesion observed as changed by at least two panels. Once patients were classified according to the above scheme, four dichotomous end points for progression or no progression were defined. The four different measures of outcome that reflect different degrees of certainty of progression of CAD of patients were defined: (l) definite lesion progression and no lesion regression, (2) definite lesion progression with or without lesion regression, (3) definite or probable lesion progression and no lesion regression, and (4) definite or probable lesion progression with or without lesion regression. For each of these measures of outcome, patients were cross-classified by treatment group and outcome; chi-square statistics were calculated for the resulting two-by-two tables to test effect of treatment on progression of disease.
In addition to the overall qualitative classification of change, we considered other important quantitative measures of angiographic change based on the number and severity of lesions that change. Appendix C (see footnote p. 315) provides definitions of quantitative change as well as methodology for calculation of standard errors and statistical hypothesis tests for quantitative measures of change. 5 Methods of multivariate analysis. Crude effects of treatment for each of the four measures of outcome of CAD were adjusted with multivariate logistic regression models to ensure that the results were not confounded by unequal distribution of risk factors between the two treatment groups.6 In this analysis the outcome variable was CAD progression and the variables used to adjust treatment effect were those that were out of balance at baseline (p < .05). Z scores are reported for treatment and for each of the baseline variables. The Z scores, which are the regression coefficients divided by their standard errors, have approximately a standard normal distribution. A positive Z score represents a positive association with CAD progression, and a negative score represents a negative association. The critical values for a one-sided test, alpha = .05, are + 1.64.
Statistical computing. Statistical Package for the Social Sciences (SPSS) programs were used for descriptive statistics. Biomedical Computer Programs P-series (BMDP) were used for logistic regression analysis. Computer storage and retrieval of data were accomplished through use of the 1022 Database Management System. The algorithms for angiographic measures of change were written specifically for this study. At the conclusion of the study, displays were designed to present lipid values and angiographic results for each ifidividual patient. Examples are given in Appendix D (see footnote p. 315). The definitions for angiographic change and the algorithm for alignment described above are illustrated in this Appendix as well.
Quality control of panels studying angiograms. To assess reader reproducibility, 18 pairs of angiograms (baseline and follow-up) selected at random were evaluated by each of the three panels a second time, at least 6 months after the first evaluation. The sample was enriched with films that exhibited confirmed lesion changes. The panels were not told that these films, which were interspersed among new pairs, had been shown previously. Assessment of 14 of the pairs was the same on the first and second reading (six no change, one mixed response, one probable progression, and six definite progression). Three pairs that were judged as showing probable progressions and one judged as showing probable regression on the first reading were classified as exhibiting no change on the CIRCULATION groups: 2% in placebo and 8% in the cholestyramine group. Although triglycerides were significantly higher in the cholestyramine group than in the placebo group at each annual follow-up, triglycerides were higher in the cholestyramine group at baseline as well. Hence, the increases in triglyceride levels over time Figure 1 displays the mean values over time for each treatment group for those items that did show a difference between treatment groups. Alkaline phosphatase and total iron-binding capacity rose and carotene values dropped in the cholestyramine group.
Side effects were evaluated through the use of a printed list answered by the patient. Each item had a choice of responses that were none, slight, moderate, and severe. Table 7 or severe side effects by treatment at (1) baseline before diet and before therapy, (2) after diet and before therapy, (3) 1 year follow-up, and (4) 5 year followup. No increase in side effects occurred during followup. In fact, the highest incidence of side effects occurred before diet and drug therapy. The only statistically significant difference between placebo and cholestyramine for any side effect at any of these four study times occurred after diet but before drug therapy. At that point there were more cholestyramine-treated patients who reported nervousness. Risk factors were monitored during follow-up. There was no significant change in blood pressure or weight for either treatment group. Smoking habits re- mained the same for most patients, although two of the placebo-treated patients and four of the cholestyramine-treated patients who smoked at baseline were not smoking at 5 year follow-up, and six of the placebotreated patients and two of the cholestyramine-treated patients who were former smokers at baseline had resumed smoking again at 5 years. Angiographic changes. Each patient was classified by change in CAD according to the qualitative categories of definite progression, probable progression, definite regression, probable regression, no change, or mixed response. Table 8 displays the results of this patient classification for the two treatment groups. Patients were then divided into two groups, either CAD progression or no progression, according to each of the four cut points for defining progression. The results are shown in table 9. First, we examined the results of progression without regression. Definite progression was identified in 35.1 % of the placebo group and in 25.4% of the cholestyramine group. This difference was not statistically significant at the .05 level. When the definite and probable progression categories were combined, progression of the coronary lesions occurred in 49.1% of the placebo group but in only 32.2% of the cholestyramine group, a result that was significant at p = .03 for a one-sided hypothesis test.
Whether the category of patients who exhibit both progression and regression of lesions represents deterioration is unclear, particularly since within the category there are different degrees of change. Among the five patients with mixed response in the cholestyramine group, one exhibited definite progression with definite regression, one exhibited probable progression with probable regression, and three exhibited definite progression with probable regression. The placebo-treated patient with mixed response had both definite progression and definite regression. In the logistic model the outcome is dichotomous. The model was fit with the four different definitions for CAD progression. As described above the first was definite progression with no'regression. The' second was definite progression with or without regression, the third was progression with no regression, and the fourth was progression with or without regression. Ta Multiple end points. Seven patients died and five had a nonfatal myocardial infarction (three of which were documented) in the placebo group, whereas five died and three had a nonfatal myocardial infarction (one of which was documented) among patients in the cholestyramine group. Seven of the eight patients with nonfatal myocardial infarction had a final angiogram. Of these seven, six were noted to have progression as determined angiographically. Death, myocardial infarction, progression, or both myocardial infarction and angiographic progression occurred in 29 cholestyramine-treated patients and in 37 placebo-treated patients. The odds that a cholestyramine-treated patient died, had a myocardial infarction, or had progression in relation to the odds that a placebo-treated patient died, had a myocardial infarction, or had progression is 0.60. A 95% confidence interval for the odds ratio is 0.30 to 1.21. An odds ratio of 1.0 indicates equal odds 322 for the undesirable outcomes. Since the 95% confidence interval includes 1.0 we can not reject the null hypothesis that the groups are the same at the alpha .05 level.
Discussion
Plasma concentrations of cholesterol and LDL cholesterol are directly related to the prevalence and incidence of CAD.7" However, although lowering the plasma concentrations of cholesterol in nonhuman primates with diet-induced hypercholesterolemia will delay the progression and actually lead to regression of existing atherosclerotic plaques,'2 16 similar effects of lowering cholesterol levels on coronary atherosclerosis have not yet been clearly shown to occur in man. 10 715
The ultimate test of a clinical hypothesis dealing with therapeutics is the double-blind, randomized, placebo-controlled clinical trial. Several primary and secondary prevention clinical trials that use diet alone'5 '7 1 2and diet plus drugs7 18. 21 have been published. None of the trials has reported conclusive results. to. 5 17 20 All the trials to date have depended on detecting differences in the clinical end points of death and heart attack to demonstrate an effect of treatment. This has necessitated long periods of follow-up and large numbers of participants. In trials that have relied on diet alone, a cholesterol differential between control and treatment groups of only about 10% and problems with patient dropouts have weakened their statistical power. 15 . 17. 8 When drugs have been added to diet to enhance the degree of cholesterol lowering, problems related in part to the metabolic effects of the drugs have interfered with the interpre.tation of the results of the trials. 20 22-25 In this study we attempted to overcome most of these problems by our choice of drug and end point. Cholestyramine, a nonabsorbed bile acid sequestering resin, was used to enhance the effects of a low-cholesterol diet. Cholestyramine has previously been shown to reduce concentrations of LDL cholesterol; it is also a drug that has no consistent physiologic effects that would compromise its use in a double-blind protocol. 21' 26 In additipn, in nonhuman primates cholestyramine has been shown to result in the regression of atherosclerotic coronary lesions in animals with both spontaneous and diet-induced hypercholesterolemia. '6 In this double-blind study in which the treatment group received cholestyramine and diet while the control group received placebo and diet, a treatment-controlled difference in LDL cholesterol of more than 20% was achieved. Since a more specific end point with a reasonably high-event rate, that is, change in the degree of coronary artery narrowing (as determined by serial coronary angiograms) was used, many fewer patients were required than in studies using clinical end points with a low-event rate. The major limitation of our study derived from our inability to recruit the 250 subjects with Type IL hyperlipoproteinemia and CAD that was projected for the statistical success of this trial.
Analysis of the data indicated that while no definitive evidence emerged indicating that therapy caused regression of disease, diet plus cholestyramine therapy substantially diminished the rate of progression of lesions when the groups of patients who were designated as exhibiting definite or probable disease progression without regression were combined. Thus, 49% of patients in the placebo group exhibited definite or probable disease progression with no regression, as compared with only 32% of the cholestyramine-treated group.
The mixed-response category was not anticipated, but because of the requirement that at least two of the three panels observed both lesion regression and progression within a single patient, we do believe mixed response is a true phenomenon. The mixed response does not represent deterioration as unambiguously as does lesion progression alone. For this reason we choose to analyze the results two ways, both excluding those patients with mixed response from the progression group and then counting those patients with mixed response with those who had clear-cut progression. Since mixed response occurred more frequently among the cholestyramine-treated patients (p = . 22 for a two-sided comparison), considering mixed response as progression diminished the effect of treatment.
When only lesions producing 50% or more luminal narrowing at entry into study were considered, 33% of the placebo group exhibited definite or probable progression, as compared with a progression rate of only 12% in the cholestyramine-treated group. This difference was significant at the .05 level. The significance of this latter finding must be viewed cautiously, since this subgroup had not been defined before initiation of the study. However, there is no mixed-response category in the subgroup and so the results are more definitive.
In the primary analysis the unit of disease status was considered to be the individual patient rather than the individual lesion. The basis for this stems from what we believe is a reasonable assumption: that lesions within a given patient do not change independently. These lesions are exposed to the same level of general risk factors associated with that particular patient (smoking, weight, age, blood pressure, and serum lipid levels). If changes in individual lesions are examined, however, results suggesting a salutary effect of diet plus cholestyramine therapy are again obtained (table 11) . While all of the analyses presented in table
